Telitacicept and low-dose steroids for stubborn myasthenia gravis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called telitacicept combined with low-dose steroids for people with myasthenia gravis that hasn't improved with standard treatments. It aims to reduce muscle weakness and improve daily function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have been diagnosed with myasthenia gravis and tested positive for the AChR antibody.
- Your symptoms are not well controlled despite standard treatment (steroids or other immune-suppressing drugs).
- You have not had a thymectomy (surgery to remove the thymus gland) in the last 6 months, and you don't have a thymic tumor.
- You don't have active infections (like shingles, HIV, tuberculosis, or hepatitis), cancer, or severe liver/kidney problems.
- You are not pregnant, breastfeeding, or planning to become pregnant during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination treatment for generalized myasthenia gravis. It combines two medications to help reduce muscle weakness and improve your daily life.
This trial tests a new immune cell treatment (CAR T-cells) for people with generalized myasthenia gravis that has not improved with standard treatments. It aims to reduce symptoms by targeting and calming the immune system's attack on muscles.
This trial tests an experimental therapy using special immune cells (UCAR T-cells) to target and destroy certain B cells that produce the antibodies causing myasthenia gravis. It's for people whose symptoms are not well controlled by standard treatments and may offer a new option.
This trial is testing a new type of cell therapy called CAR-T that targets two proteins (CD19 and BCMA) on certain immune cells. It aims to help people with severe myasthenia gravis that has not improved with standard treatments.
This trial is testing a new medication called telitacicept to see if it can help children with eye muscle weakness from myasthenia gravis. It aims to find a more effective and safe treatment for this condition, which can affect vision and daily activities.
This trial tests a new drug, telitacicept, for people with myasthenia gravis that only affects the eyes (ocular myasthenia gravis). The goal is to see if it can improve symptoms like droopy eyelids or double vision.
Hear when a new Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.